HIGHLIGHTS
- who: Brandon J. Beddingfield et al. from the University of Cambridge, United Kingdom have published the Article: Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques, in the Journal: (JOURNAL)
- what: The clinical trial focusing on emergency department CP treatment (NHLBI C3PO) was discontinued , and the RECOVERY trial showed no difference in 28-day mortality with or without treatment with CP . The authors demonstrate that CP that is of insufficient titer does not alter most Tissue vRNA Content post SARS-CoV-2 Challenge.
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.